Golden Biotechnology Corporation

Golden Biotechnology Corporation is an advanced biopharmaceutical company specializing in drug discovery and the development of innovative therapeutics and health supplements. Founded in 2002 and headquartered in New Taipei City, Taiwan, the company focuses on addressing high unmet medical needs within the healthcare sector, particularly in oncology, cardio-metabolic syndromes, autoimmune disorders, neurodegenerative diseases, and infectious diseases. Its lead compound, Antroquinonol, has been the subject of multiple Phase 1 and 2 clinical trials targeting conditions such as non-small cell lung cancer, pancreatic cancer, acute myeloid leukemia, hyperlipidemia, hepatitis B, COVID-19, and Alzheimer’s disease. Golden Biotechnology also engages in the production and sale of health foods and herbal supplements, including products like antrodia camphorata mycelium capsules. The company holds over 150 patents in more than 40 countries, emphasizing global collaboration through licensing and joint ventures to expand its reach. Golden Biotechnology Corporation plays a significant role in Taiwan’s pharmaceutical and biotechnology industries by pursuing innovative drug development and maintaining PIC/S GMP-certified facilities for future clinical and commercial expansion.